Myth-buster
B vitamins lowered homocysteine by 2.36 µmol/L in heart patients — but didn't reduce heart attacks or deaths.
This meta-analysis confirms that combined B9, B6, and B12 supplementation reliably drops homocysteine, yet that lab improvement didn't translate into fewer major cardiovascular events — a reminder that a biomarker win isn't always a clinical win.
In a meta-analysis of 539 coronary heart disease patients, combined B-vitamin supplements (folic acid, B6, B12) lowered homocysteine levels by an average of 2.36 units — a statistically significant drop. However, the same analysis found no reduction in major cardiovascular events or cardiovascular mortality, meaning the benefit was limited to a lab value and a reduction in artery re-narrowing (restenosis), not to the outcomes that matter most to patients.
Where this fits in the evidence
Pillser has synthesized 6 studies on Vitamin B9 for Reduced Homocysteine Level — overall evidence strength: High.
Across 6 studies, 5 reported beneficial effects on reducing homocysteine levels, with effect sizes ranging from small to large (mixed). The median study duration was 84 days (12 weeks), indicating effects typically observed at that timeframe. Most studies used doses of 400 μg to 1 mg per day in diverse adult populations, including healthy adults, patients with coronary heart disease, and those with type 2 diabetes.
The study
- Meta-Analysis
- n = 539
- 2026-01-30
- Annals of medicine
This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.